New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
Posters
Fit-for-purpose validation and inter-laboratory cross-validation of a TBNK flow cytometry assay with improved B cell monitoring capabilities
April 14, 2026
More infoPosters
Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS
April 14, 2026
More infoCellTalk Blog
Rescuing a Pilot Study: How a Coordinated Response From CellCarta Kept a Critical Program on Track
April 14, 2026
More info